Isoaspartyl post-translational modification triggers anti-tumor T and B lymphocyte immunity

被引:48
作者
Doyle, Hester A.
Zhou, Jing
Wolff, Martin J.
Harvey, Bohdan P.
Roman, Robert M.
Gee, Renelle J.
Koski, Raymond A.
Mamula, Mark J.
机构
[1] Yale Univ, Sch Med, New Haven, CT 06520 USA
[2] L2 Diagnost, New Haven, CT 06511 USA
关键词
D O I
10.1074/jbc.M604847200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A hallmark of the immune system is the ability to ignore self-antigens. In attempts to bypass normal immune tolerance, a post-translational protein modification was introduced into self-antigens to break T and B cell tolerance. We demonstrate that immune tolerance is bypassed by immunization with a post-translationally modified melanoma antigen. In particular, the conversion of an aspartic acid to an isoaspartic acid within the melanoma antigen tyrosinase-related protein (TRP)-2 peptide-(181-188) makes the otherwise immunologically ignored TRP-2 antigen immunogenic. Tetramer analysis of isoAsp TRP-2 peptide- immunized mice demonstrated that CD8(+) T cells not only recognized the isoaspartyl TRP-2 peptide but also the native TRP-2 peptide. These CD8(+) T cells functioned as cytotoxic T lymphocytes, as they effectively lysed TRP-2 peptide-pulsed targets both in vitro and in vivo. Potentially, post-translational protein modification can be utilized to trigger strong immune responses to either tumor proteins or potentially weakly immunogenic pathogens.
引用
收藏
页码:32676 / 32683
页数:8
相关论文
共 41 条
[1]   The paradox of T cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma [J].
Anichini, A ;
Vegetti, C ;
Mortarini, R .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2004, 53 (10) :855-864
[2]   An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions [J].
Anichini, A ;
Molla, A ;
Mortarini, R ;
Tragni, G ;
Bersani, I ;
Di Nicola, M ;
Gianni, AM ;
Pilotti, S ;
Dunbar, R ;
Cerundolo, V ;
Parmiani, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (05) :651-667
[3]   CD8+T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells [J].
Antony, PA ;
Piccirillo, CA ;
Akpinarli, A ;
Finkelstein, SE ;
Speiss, PJ ;
Surman, DR ;
Palmer, DC ;
Chan, CC ;
Klebanoff, CA ;
Overwijk, WW ;
Rosenberg, SA ;
Restifo, NP .
JOURNAL OF IMMUNOLOGY, 2005, 174 (05) :2591-2601
[4]   Dendritic cells as therapeutic vaccines against cancer [J].
Banchereau, J ;
Palucka, AK .
NATURE REVIEWS IMMUNOLOGY, 2005, 5 (04) :296-306
[5]   Presence and localization of T-cell subsets in relation to melanocyte differentiation antigen expression and tumour regression as assessed by immunohistochemistry and molecular analysis of microdissected T cells [J].
Bernsen, MR ;
Diepstra, JHS ;
van Mil, P ;
Punt, CAJ ;
Figdor, CG ;
van Muijen, GNP ;
Adema, GJ ;
Ruiter, DJ .
JOURNAL OF PATHOLOGY, 2004, 202 (01) :70-79
[6]  
BROWNE WB, 1999, J EXP MED, V190, P1717
[7]  
CLARKE S, 1985, ANNU REV BIOCHEM, V54, P479, DOI 10.1146/annurev.biochem.54.1.479
[8]  
CLARKE S, 1992, STABILITY PROTEIN PH, P2
[9]  
Corthay A, 1998, EUR J IMMUNOL, V28, P2580, DOI 10.1002/(SICI)1521-4141(199808)28:08<2580::AID-IMMU2580>3.0.CO
[10]  
2-X